| __timestamp | Bristol-Myers Squibb Company | Zoetis Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 1643000000 |
| Thursday, January 1, 2015 | 5001000000 | 1532000000 |
| Friday, January 1, 2016 | 5002000000 | 1364000000 |
| Sunday, January 1, 2017 | 4849000000 | 1334000000 |
| Monday, January 1, 2018 | 4551000000 | 1484000000 |
| Tuesday, January 1, 2019 | 4871000000 | 1638000000 |
| Wednesday, January 1, 2020 | 7661000000 | 1726000000 |
| Friday, January 1, 2021 | 7690000000 | 2001000000 |
| Saturday, January 1, 2022 | 7814000000 | 2009000000 |
| Sunday, January 1, 2023 | 7772000000 | 2151000000 |
| Monday, January 1, 2024 | 8414000000 | 2318000000 |
Data in motion
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. From 2014 to 2023, Bristol-Myers Squibb Company and Zoetis Inc. have shown distinct approaches to handling these costs. Bristol-Myers Squibb's SG&A expenses have fluctuated, peaking in 2022 with a 37% increase from 2018. In contrast, Zoetis Inc. has maintained a more consistent trajectory, with a steady rise of approximately 61% over the same period. This suggests that while Bristol-Myers Squibb has experienced volatility, Zoetis has managed its SG&A costs with greater stability. As investors and industry analysts look for efficient cost management, Zoetis's approach may offer a model of consistency and growth. Understanding these trends provides valuable insights into the strategic financial management of these industry giants.
Who Optimizes SG&A Costs Better? Eli Lilly and Company or Zoetis Inc.
Selling, General, and Administrative Costs: Novartis AG vs Zoetis Inc.
Revenue Insights: Bristol-Myers Squibb Company and Zoetis Inc. Performance Compared
Bristol-Myers Squibb Company or GSK plc: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Bristol-Myers Squibb Company vs MannKind Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Geron Corporation
SG&A Efficiency Analysis: Comparing Bristol-Myers Squibb Company and Celldex Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Zoetis Inc. and Incyte Corporation
Comparing SG&A Expenses: Zoetis Inc. vs Lantheus Holdings, Inc. Trends and Insights
Selling, General, and Administrative Costs: Zoetis Inc. vs MorphoSys AG
Breaking Down SG&A Expenses: Zoetis Inc. vs Celldex Therapeutics, Inc.